 |
88 Diseases |  |
13 Trials |
|
13 Trials |  |
791 News |  |
| «123456789101112» |
- ||| Musredo (molidustat) / Bayer
Enrollment closed, Enrollment change: DIALOGUE5: Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Nov 5, 2015
P2, N=88, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=148 --> 88
- ||||| pegol sihematide (EPO-018B) / Jiangsu Hansoh Pharma
New P2 trial: Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis (clinicaltrials.gov) - Oct 26, 2015
P2, N=60, Recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- || Musredo (molidustat) / Bayer
Trial primary completion date: DIALOGUE4: Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Oct 22, 2015
P2, N=201, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=148 --> 88 Trial primary completion date: Jan 2016 --> Oct 2015
- ||| Epogen (epoetin alfa) / Amgen
Enrollment closed, Trial primary completion date: Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis (clinicaltrials.gov) - Oct 14, 2015
P4, N=217, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2016 --> Oct 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> May 2016
- Epogen (epoetin alfa) / Amgen
New P2 trial: Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial (clinicaltrials.gov) - Oct 1, 2015
P2, N=40, Not yet recruiting, Sponsor: University of California, San Diego
- Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen
Trial completion: Treatment With Erythropoietin and Cognition During Hypoglycaemia (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=11, Completed, Sponsor: Hillerod Hospital, Denmark
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> May 2016 Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial completion: FRIEMAX: Efficacy Study of Epoetin Alfa in Friedreich Ataxia (clinicaltrials.gov) - Aug 12, 2015
P2, N=56, Completed, Sponsor: Federico II University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen
Trial completion, Trial primary completion date: Erythropoietin in Traumatic Brain Injury (EPO-TBI) (clinicaltrials.gov) - Jul 20, 2015
P3, N=606, Completed, Sponsor: Australian and New Zealand Intensive Care Research Centre
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2015
- Epogen (epoetin alfa) / Amgen
New trial: Cross Iron (Comparative Randomized Oral Versus Systemic IRON) (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=100, Recruiting, Sponsor: University Hospital, Montpellier
- ||| Musredo (molidustat) / Bayer
Enrollment closed: DIALOGUE4: Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Jul 14, 2015
P2, N=201, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2015 Recruiting --> Active, not recruiting
- ||| Epogen (epoetin alfa) / Amgen
Enrollment change: A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins (clinicaltrials.gov) - Jun 30, 2015
P4, N=4670, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Active, not recruiting N=15000 --> 4670
- || Epogen (epoetin alfa) / Amgen
Trial primary completion date: A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment (clinicaltrials.gov) - Jun 16, 2015
P1, N=107, Completed, Sponsor: Hospira, Inc.
N=15000 --> 4670 Trial primary completion date: May 2011 --> Jan 2011
- || Musredo (molidustat) / Bayer
Trial primary completion date: DIALOGUE4: Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Jun 11, 2015
P2, N=188, Recruiting, Sponsor: Bayer
Trial primary completion date: May 2011 --> Jan 2011 Trial primary completion date: Oct 2015 --> Jan 2016
- Epogen (epoetin alfa) / Amgen, Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
Enrollment change, Trial termination, Trial primary completion date: The Benefits of a Preoperative Anemia Management Program (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=51, Terminated, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Oct 2015 --> Jan 2016 N=500 --> 51 | Recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Jan 2015
- | Epogen (epoetin alfa) / Amgen
Enrollment closed: Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) (clinicaltrials.gov) - May 28, 2015
P1/2, N=50, Active, not recruiting, Sponsor: University of California, San Francisco
N=500 --> 51 | Recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Jan 2015 Recruiting --> Active, not recruiting
- |||| Epogen (epoetin alfa) / Amgen
Enrollment open: Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis (clinicaltrials.gov) - Apr 20, 2015
P4, N=200, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Epogen (epoetin alfa) / Amgen
Trial primary completion date: An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Apr 19, 2015
P3, N=131, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2015 --> Dec 2015
- ||||| Evrenzo (roxadustat) / FibroGen
Enrollment change, Trial primary completion date: Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis (clinicaltrials.gov) - Apr 19, 2015
P3, N=600, Recruiting, Sponsor: FibroGen
Trial primary completion date: Jan 2015 --> Dec 2015 N=1200 --> 600 | Trial primary completion date: Dec 2016 --> Jun 2017
- ||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment change, Trial primary completion date: Himalayas: Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (clinicaltrials.gov) - Apr 19, 2015
P3, N=750, Recruiting, Sponsor: FibroGen
N=1200 --> 600 | Trial primary completion date: Dec 2016 --> Jun 2017 N=1000 --> 750 | Trial primary completion date: May 2016 --> Jun 2017
- | Epogen (epoetin alfa) / Amgen
Phase classification: Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin (clinicaltrials.gov) - Mar 24, 2015
P4, N=4761, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=1000 --> 750 | Trial primary completion date: May 2016 --> Jun 2017 Phase classification: P=N/A --> P4
- ||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment change: Himalayas: Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (clinicaltrials.gov) - Mar 7, 2015
P3, N=1000, Recruiting, Sponsor: FibroGen
Phase classification: P=N/A --> P4 N=750 --> 1000
- Epogen (epoetin alfa) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) (clinicaltrials.gov) - Feb 27, 2015
P2, N=56, Completed, Sponsor: Mathew S. Maurer
N=750 --> 1000 Active, not recruiting --> Completed | N=80 --> 56 | Trial primary completion date: Mar 2012 --> Nov 2012
- |||||| Evrenzo (roxadustat) / FibroGen
Enrollment open: Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis (clinicaltrials.gov) - Feb 13, 2015
P3, N=1200, Recruiting, Sponsor: FibroGen
Active, not recruiting --> Completed | N=80 --> 56 | Trial primary completion date: Mar 2012 --> Nov 2012 Not yet recruiting --> Recruiting
- ||| Musredo (molidustat) / Bayer
Enrollment change: DIALOGUE4: Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Jan 13, 2015
P2, N=188, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting N=148 --> 188
- | Epogen (epoetin alfa) / Amgen
New P2 trial: Efficacy Study of Zinc Supplementation on Anemia, Oxidative Stress and Inflammation in Hemodialysis Patients (clinicaltrials.gov) - Jan 12, 2015
P2, N=60, Recruiting, Sponsor: Ain Shams University
- |||| Evrenzo (roxadustat) / FibroGen
Trial primary completion date: Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (clinicaltrials.gov) - Jan 7, 2015
P3, N=750, Recruiting, Sponsor: Astellas Pharma Europe B.V.
N=148 --> 188 Trial primary completion date: Sep 2016 --> Mar 2017
- Epogen (epoetin alfa) / Amgen
Trial primary completion date: Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (clinicaltrials.gov) - Jan 2, 2015
P3, N=114, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Sep 2016 --> Mar 2017 Trial primary completion date: Nov 2003 --> Jan 2010
- |||||| Evrenzo (roxadustat) / FibroGen
Enrollment open: Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (clinicaltrials.gov) - Nov 23, 2014
P3, N=750, Recruiting, Sponsor: Astellas Pharma Europe B.V.
Trial primary completion date: Nov 2003 --> Jan 2010 Not yet recruiting --> Recruiting
- | Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen
Enrollment closed, Trial primary completion date: Erythropoietin in Traumatic Brain Injury (EPO-TBI) (clinicaltrials.gov) - Nov 5, 2014
P3, N=606, Active, not recruiting, Sponsor: Australian and New Zealand Intensive Care Research Centre
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Dec 2014
- |||||||||| Evrenzo (roxadustat) / FibroGen
New P3 trial: Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (clinicaltrials.gov) - Oct 30, 2014
P3, N=750, Not yet recruiting, Sponsor: Astellas Pharma Europe B.V.
- || Musredo (molidustat) / Bayer
Trial primary completion date: DIALOGUE5: Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Oct 28, 2014
P2, N=148, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Dec 2014 Trial primary completion date: Aug 2017 --> Sep 2018
- |||||||||| Evrenzo (roxadustat) / FibroGen
New P3 trial: Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis (clinicaltrials.gov) - Oct 24, 2014
P3, N=1200, Not yet recruiting, Sponsor: FibroGen
- | Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Phase classification: Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy (clinicaltrials.gov) - Oct 17, 2014
P2, N=320, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Aug 2017 --> Sep 2018 Phase classification: P=N/A --> P2
- || Musredo (molidustat) / Bayer
Trial primary completion date: DIALOGUE4: Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Oct 2, 2014
P2, N=148, Recruiting, Sponsor: Bayer
Phase classification: P=N/A --> P2 Trial primary completion date: Dec 2014 --> Aug 2015
- ||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment change: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. (clinicaltrials.gov) - Oct 2, 2014
P3, N=1425, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2014 --> Aug 2015 N=2850 --> 1425
- ||||| Epogen (epoetin alfa) / Amgen
New P4 trial: Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis (clinicaltrials.gov) - Oct 2, 2014
P4, N=200, Not yet recruiting, Sponsor: Amgen
- Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen
Trial primary completion date: Erythropoietin in Traumatic Brain Injury (EPO-TBI) (clinicaltrials.gov) - Aug 8, 2014
P3, N=606, Recruiting, Sponsor: Australian and New Zealand Intensive Care Research Centre
N=2850 --> 1425 Trial primary completion date: May 2014 --> Apr 2015
- |||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment open: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. (clinicaltrials.gov) - Jul 14, 2014
P3, N=2850, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: May 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- |||| Epogen (epoetin alfa) / Amgen
Trial primary completion date: An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 26, 2014
P3, N=131, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2014 --> Jan 2015
- |||||||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
New P3 trial: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. (clinicaltrials.gov) - Jun 26, 2014
P3, N=2850, Not yet recruiting, Sponsor: AstraZeneca
- ||| Epogen (epoetin alfa) / Amgen
Trial initiation date: OETNA: Optimized Erythropoietin (EPO) Treatment (clinicaltrials.gov) - Jun 17, 2014
P2, N=62, Recruiting, Sponsor: University of Iowa
Trial primary completion date: Mar 2014 --> Jan 2015 Initiation date: Feb 2014 --> Jun 2014
- |||| Epogen (epoetin alfa) / Amgen
Enrollment open, Trial initiation date: OETNA: Optimized Erythropoietin (EPO) Treatment (clinicaltrials.gov) - Jun 17, 2014
P2, N=62, Recruiting, Sponsor: University of Iowa
Initiation date: Feb 2014 --> Jun 2014 Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jun 2014
- Epogen (epoetin alfa) / Amgen
New P2 trial: Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI (clinicaltrials.gov) - May 26, 2014
P2, N=30, Not yet recruiting, Sponsor: Uniformed Services University of the Health Sciences
- ||| Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Enrollment closed: A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) (clinicaltrials.gov) - May 18, 2014
P4, N=2828, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jun 2014 Recruiting --> Active, not recruiting
- || Musredo (molidustat) / Bayer
Trial completion date: DIALOGUE5: Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - May 14, 2014
P2, N=148, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial completion date: Aug 2017 --> Sep 2017
- |||| Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Enrollment open: A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) (clinicaltrials.gov) - May 4, 2014
P4, N=2800, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Aug 2017 --> Sep 2017 Active, not recruiting --> Recruiting
- ||||| Epogen (epoetin alfa) / Amgen, Omontys (peginesatide) / Affymax
Trial initiation date: DIAMOND: Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Apr 28, 2014
P3, N=184, Completed, Sponsor: Takeda
Active, not recruiting --> Recruiting Initiation date: Sep 2011 --> Oct 2011
- ||| Musredo (molidustat) / Bayer
Trial initiation date: DIALOGUE5: Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Apr 14, 2014
P2, N=148, Recruiting, Sponsor: Bayer
Initiation date: Sep 2011 --> Oct 2011 Initiation date: Mar 2014 --> Apr 2014
- |||| Musredo (molidustat) / Bayer
Enrollment open: DIALOGUE5: Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (clinicaltrials.gov) - Apr 14, 2014
P2, N=148, Recruiting, Sponsor: Bayer
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- Epogen (epoetin alfa) / Amgen
Enrollment open: Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) (clinicaltrials.gov) - Apr 10, 2014
P1/2, N=50, Recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting